Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $17 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a Buy rating on Recursion Pharmaceuticals (NASDAQ:RXRX) and maintained a $17 price target.
April 09, 2024 | 10:20 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum reiterates a Buy rating on Recursion Pharmaceuticals with a $17 price target.
The reiteration of a Buy rating and maintenance of a $17 price target by a reputable analyst could positively influence investor sentiment towards RXRX, potentially driving its stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100